November 07, 2023
1 min watch
Save
VIDEO: Alectinib effective in early-stage ALK-positive NSCLC
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
MADRID — In a video interview, Julia Rotow, MD, discussed positive data from the ALINA study in ALK-positive non-small cell lung cancer presented at ESMO Congress.
The study showed that alectinib (Alecensa, Genentech) significantly improved DFS compared with chemotherapy in early-stage patients with resected ALK-positive NSCLC.
“As we return home, I expect to see approvals in this space and really should now be screening all of our early-stage patients not just for EGFR, but also for ALK to get them optimal adjuvant therapy options,” Rotow, clinical director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, told Healio.
Reference:
- Solomon B, et al. Abstract LBA2. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Rotow reports numerous ties to industry.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.